(19)
(11) EP 4 133 106 A1

(12)

(43) Date of publication:
15.02.2023 Bulletin 2023/07

(21) Application number: 21717451.5

(22) Date of filing: 09.04.2021
(51) International Patent Classification (IPC): 
C12Q 1/6886(2018.01)
(52) Cooperative Patent Classification (CPC):
C12Q 2600/118; C12Q 2600/158; C12Q 2600/112; C12Q 1/6886
(86) International application number:
PCT/EP2021/059347
(87) International publication number:
WO 2021/205024 (14.10.2021 Gazette 2021/41)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 09.04.2020 EP 20315145

(71) Applicants:
  • Centre Léon Bérard
    69008 Lyon (FR)
  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM
    75013 Paris (FR)
  • Centre national de la recherche scientifique
    75016 Paris (FR)
  • Université Claude Bernard Lyon 1
    69100 Villeurbanne (FR)

(72) Inventors:
  • CAUX, Christophe
    01360 BRESSOLLES (FR)
  • VALLADEAU-GUILEMOND, Jenny
    69970 MARENNES (FR)
  • HUBERT, Margaux
    69008 LYON (FR)

(74) Representative: Lavoix 
62, rue de Bonnel
69448 Lyon Cedex 03
69448 Lyon Cedex 03 (FR)

   


(54) TYPE III INTERFERON FOR USE AS A BIOMARKER TO PREDICT RESPONSE TO A CANCER TREATMENT